Edison Pharmaceuticals
CompanyUnited StatesFounded 2005
Edison Pharmaceuticals develops one asset, in phase 3, no development reported (Vatiquinone in Friedreich ataxia). Mostly small molecule acting on NQO1; based in the United States, founded in 2005.
- 1
- Asset
- Furthest stage
- Phase 3, no development reported
- Raised
- $80.2M
- 4
- Trials
- 0
- Signals
Pipeline
1Inhibits 15-lipoxygenase to reduce lipid peroxidation and ferroptotic cell death.
Phase 3, no development reported, Small molecule, NQO1, Friedreich ataxia, Alpers' disease (Phase 2)
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials7
- Funding rounds and grants6
- Similar companies6